HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial (Q30538743)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

16 August 2017

HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial (English)

1 reference

Europe PubMed Central

16 August 2017

phase II clinical trial

0 references

object named as

Gemma G Kenter

15

0 references

Cornelis J. M. Melief

14

object named as

Cornelis J M Melief

1 reference

Europe PubMed Central

16 August 2017

Sjoerd H van der Burg

16

object named as

Sjoerd H van der Burg

1 reference

Europe PubMed Central

16 August 2017

author name string

Mariette I E van Poelgeest

1

1 reference

Europe PubMed Central

16 August 2017

Marij J P Welters

2

1 reference

Europe PubMed Central

16 August 2017

Edith M G van Esch

3

1 reference

Europe PubMed Central

16 August 2017

Linda F M Stynenbosch

4

1 reference

Europe PubMed Central

16 August 2017

Gijs Kerpershoek

5

1 reference

Europe PubMed Central

16 August 2017

Els L van Persijn van Meerten

6

1 reference

Europe PubMed Central

16 August 2017

Muriel van den Hende

7

1 reference

Europe PubMed Central

16 August 2017

Margriet J G Löwik

8

1 reference

Europe PubMed Central

16 August 2017

Dorien M A Berends-van der Meer

9

1 reference

Europe PubMed Central

16 August 2017

Lorraine M Fathers

10

1 reference

Europe PubMed Central

16 August 2017

A Rob P M Valentijn

11

1 reference

Europe PubMed Central

16 August 2017

Jaap Oostendorp

12

1 reference

Europe PubMed Central

16 August 2017

Gert Jan Fleuren

13

1 reference

Europe PubMed Central

16 August 2017

publication date

4 April 2013

1 reference

Europe PubMed Central

16 August 2017

Journal of Translational Medicine

1 reference

Europe PubMed Central

16 August 2017

11

1 reference

Europe PubMed Central

16 August 2017

88

1 reference

Europe PubMed Central

16 August 2017

https://scigraph.springernature.com/pub.10.1186/1479-5876-11-88

0 references

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3623745

20 June 2018

The simultaneous ex vivo detection of low-frequency antigen-specific CD4+ and CD8+ T-cell responses using overlapping peptide pools.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3623745

20 June 2018

Coordinated regulation of myeloid cells by tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3623745

20 June 2018

Targeting regulatory T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3623745

20 June 2018

Harmonization of immune biomarker assays for clinical studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3623745

20 June 2018

M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3623745

20 June 2018

Therapeutic vaccination against human papilloma virus induced malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3623745

20 June 2018

A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3623745

20 June 2018

Improved endpoints for cancer immunotherapy trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3623745

20 June 2018

Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3623745

20 June 2018

Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3623745

20 June 2018

Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3623745

20 June 2018

The anticancer immune response: indispensable for therapeutic success?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3623745

20 June 2018

Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3623745

20 June 2018

Chemotherapy for advanced, recurrent, and metastatic cervical cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3623745

20 June 2018

Management of metastatic cervical cancer: review of the literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3623745

20 June 2018

Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3623745

20 June 2018

Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3623745

20 June 2018

Multiple CD4 and CD8 T-cell activation parameters predict vaccine efficacy in vivo mediated by individual DC-activating agonists

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3623745

20 June 2018

Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3623745

20 June 2018

The causal relation between human papillomavirus and cervical cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3623745

20 June 2018

Papillomavirus infections--a major cause of human cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3623745

20 June 2018

CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3623745

20 June 2018

Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3623745

20 June 2018

Clinical patterns of tumor recurrence after radical hysterectomy in stage IB cervical carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3623745

20 June 2018

Cancer of the Uterine Cervix

1 reference

https://api.crossref.org/works/10.1186%2F1479-5876-11-88

21 January 2018

Natural history of cervicovaginal papillomavirus infection in young women.

1 reference

https://api.crossref.org/works/10.1186%2F1479-5876-11-88

21 January 2018

Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA-DQ and -DP as a restriction element.

1 reference

https://api.crossref.org/works/10.1186%2F1479-5876-11-88

21 January 2018

Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1186%2F1479-5876-11-88

21 January 2018

Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model

1 reference

https://api.crossref.org/works/10.1186%2F1479-5876-11-88

21 January 2018

Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: which variable determines survival of cervical cancer patients?

1 reference

https://api.crossref.org/works/10.1186%2F1479-5876-11-88

21 January 2018

T Cell Assays and MIATA: The Essential Minimum for Maximum Impact

1 reference

https://api.crossref.org/works/10.1186%2F1479-5876-11-88

21 January 2018

Recurrent cervical carcinoma after radical hysterectomy

1 reference

https://pubmed.ncbi.nlm.nih.gov/23557172

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23557172

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Human Papillomavirus Type 16-Positive Cervical Cancer Is Associated with Impaired CD4+ T-Cell Immunity against Early Antigens E2 and E6

1 reference

https://pubmed.ncbi.nlm.nih.gov/23557172

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Human papillomavirus infection is transient in young women: a population-based cohort study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23557172

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidemiology of Genital Human Papillomavirus Infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/23557172

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High Number of Intraepithelial CD8+Tumor-Infiltrating Lymphocytes Is Associated with the Absence of Lymph Node Metastases in Patients with Large Early-Stage Cervical Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23557172

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Macrophages, inflammation and risk of cervical intraepithelial neoplasia (CIN) progression--clinicopathological correlation

1 reference

https://pubmed.ncbi.nlm.nih.gov/23557172

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity

1 reference

https://pubmed.ncbi.nlm.nih.gov/23557172

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine

1 reference

https://pubmed.ncbi.nlm.nih.gov/23557172

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+ T-Cell Infiltration and Survival of Patients with Cervical Carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23557172

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The detection of circulating human papillomavirus-specific T cells is associated with improved survival of patients with deeply infiltrating tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/23557172

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunotherapy for persistent viral infections and associated disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23557172

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Addition of interferon-α to the p53-SLP® vaccine results in increased production of interferon-γ in vaccinated colorectal cancer patients: a phase I/II clinical trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/23557172

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Estimates of the world-wide prevalence of cancer for 25 sites in the adult population

1 reference

https://pubmed.ncbi.nlm.nih.gov/23557172

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1479-5876-11-88

1 reference

Europe PubMed Central

16 August 2017

Dimensions Publication ID

1 reference

9 September 2019

https://scigraph.springernature.com/pub.10.1186/1479-5876-11-88

1 reference

Europe PubMed Central

16 August 2017

1 reference

Europe PubMed Central

16 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30538743&oldid=2142144612"